Pharsight

Caldolor patents expiration

CALDOLOR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9114068 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US8735452 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9649284 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US8871810 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9295639 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9138404 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9012508 CUMBERLAND PHARMS Administration of intravenous ibuprofen
Sep, 2030

(6 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(8 years from now)

US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(8 years from now)

Caldolor is owned by Cumberland Pharms.

Caldolor contains Ibuprofen.

Caldolor has a total of 9 drug patents out of which 0 drug patents have expired.

Caldolor was authorised for market use on 11 June, 2009.

Caldolor is available in solution;intravenous dosage forms.

Caldolor can be used as methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof, methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition, methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition, management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity, methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval, management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof.

The generics of Caldolor are possible to be released after 16 March, 2032.

Drug Exclusivity Drug Exclusivity Expiration
M (M) Nov 19, 2024

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval; Management of mild to moderate pain, manage...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CALDOLOR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic